<DOC>
	<DOCNO>NCT00361036</DOCNO>
	<brief_summary>A double arm ( non-inferiority ) 44 patient study assess performance BeadBlock™ treatment uterine fibroid embolization respect clinical &amp; image outcome comparison primary safety endpoint Embosphere .</brief_summary>
	<brief_title>Comparison Study Treatment Uterine Fibroids Uterine Fibroid Embolization Using BeadBlock™ Embolic Agent</brief_title>
	<detailed_description>The purpose study conduct comparison BeadBlock™ Embosphere uterine fibroid embolization . Baseline follow-up MR Imaging data make respect change fibroid uterus perfusion fibroid uterine volume . This 12 month study ( 12 month follow enrollee ) . The primary end-point degree fibroid devascularization see contrast-enhanced MRI perform 3 month ( +/- 15 day ) UAE procedure . In addition ass symptom reduction patient undergone uterine fibroid embolization Bead Block™ Embosphere® . Primary Objective 1 . To assess change fibroid devascularization see contrast-enhanced MRI perform UAE three ( 3 ) month ( +/- 15 day ) follow UAE , compare change BeadBlock™ Embosphere . Secondary Objective 1 . To assess change fibroid devascularization see contrast-enhanced MRI perform several day UAE 6 month ( +/- 15 day ) follow UAE , compare change BeadBlock™ Embosphere . Tertiary Objective 1 . To assess change uterine volume see contrast-enhanced MRI perform several day UAE , 3 month ( +/- 15 day ) 6 month ( +/- 15 day ) follow UAE , compare change BeadBlock™ Embosphere . 2 . To assess change baseline symptom severity ( UFS-QOL ) 3 , 6 12 month ( +/- 15 day ) follow-up , measure subscale UFS questionnaire , compare change BeadBlock™ Embosphere .</detailed_description>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<mesh_term>Uterine Neoplasms</mesh_term>
	<mesh_term>Leiomyomatosis</mesh_term>
	<criteria>1 . Patient chooses participate sign informed consent 2 . Age 30 50 year old 3 . Symptoms cause uterine fibroid , heavy bleeding ( menorrhagia ) and/or bulkrelated complaint urinary frequency , constipation pelvic pain . 4 . Patient fibroid confirm MRI 5 . Patient normal kidney function . 6 . Patient willing able undergo followup image 3 6 month post UFE . 1 . Patients pregnant plan become pregnant within study period , desire future fertility . 2 . Patients history gynecologic malignancy 3 . Patients know endometrial hyperplasia 4 . Patients adenomyosis 5 . Patients pelvic inflammatory disease 6 . Patients Uteri &lt; 250 ml ( cm ) calculate volume &gt; 24 week 7 . Patients pedunculated subserosal fibroid narrow attachment ( &lt; 50 % diameter fibroid ) uterus . 8 . Patients pelvic pain dominant syndrome 9 . Known allergy contrast medium adequately premedicated . 10 . Patients suitable arterial access . 11 . Previous uterine artery embolization attempt . 12 . History pelvic irradiation . 13 . Patients GnRH Therapy within 36 month prior study enrollment .</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Leiomyoma</keyword>
	<keyword>Leiomyomatosis</keyword>
	<keyword>Uterine Neoplasms</keyword>
	<keyword>BeadBlock</keyword>
	<keyword>Embsophere</keyword>
	<keyword>Embolization</keyword>
	<keyword>Uterine fibroid embolization</keyword>
</DOC>